# Ruixun Biological

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ruixun-biological

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.rainsurebio.com
- Latest round: Series C (Dec 9, 2024)
- Investors on record: 8

## About

Established in 2017 and based in Suzhou, China, Ruixun Biological is a digital PCR instrument developer and manufacturer that provides digital PCR instruments, reagents and consumables. In July 2017, the company settled in Suzhou BioBay. Chinese Academy of Sciences, Tsinghua University and Shanghai Jiaotong University cooperate with Ruixun Biological. PreciGenome LLC located in Silicon Valley, USA is the wholly owned subsidiary of the company. In December 2024, Ruixun Biological closed a series C2 funding led by Rivercity Investment.

Ruixun Biological provides equipment system in the field of molecular diagnostics and genetic testing, and adopts microfluidics, optics, precision instrumentation, electrical engineering and biochemical technologies. Its products include DPCR kits products, microfluidic products. DPCR kits products include COVID-19 RT-PCR detection kit, human leukemia biomarker test kit and DPCR RUO kits. Microfluidic products include PG-MFC flow controller, reservoir connector and cell perfusion culture system. Ruixun Biological also provides digital PCR technology services, which is a new way of absolute quantification, and it develops DropDx-2044 digital PCR system.

The company generates revenue by developing and manufacturing digital PCR (polymerase chain reaction) instruments.

The company will use the series C2 funding for clinical registration of digital PCR products at home and abroad, European market promotion and new product development.

## Funding rounds

- Series C, Dec 9, 2024 — Rivercity Investment
- Series C, Nov 17, 2022 — Qiandao Investment Fund Management
- Series B, Feb 23, 2021 — Zero2IPO Ventures, Kaitai Capital, Future Capital Discovery Advisory (Hong Kong) Limited, Volcanics Venture
- Series A, Sep 25, 2019 — YuanBio Venture, Future Capital Discovery Advisory (Hong Kong) Limited, Volcanics Venture
- Angel, Nov 20, 2017 — ZhenFund, Volcanics Venture

## Investors

- ZhenFund (https://capitalatlas.ai/funds/zhenfund) — Angel
- Volcanics Venture (https://capitalatlas.ai/funds/volcanics-venture) — Angel, Series A, Series B
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series A
- Future Capital Discovery Advisory (Hong Kong) Limited (https://capitalatlas.ai/funds/future-capital-discovery-advisory-hong-kong-limited) — Series A, Series B
- Zero2IPO Ventures (https://capitalatlas.ai/funds/zero2ipo-ventures) — Series B
- Kaitai Capital (https://capitalatlas.ai/funds/kaitai-capital) — Series B
- Qiandao Investment Fund Management (https://capitalatlas.ai/funds/qiandao-investment-fund-management) — Series C
- Rivercity Investment (https://capitalatlas.ai/funds/rivercity-investment) — Series C